GlaxoSmithKline (GSK) on Monday announced that in partnership with US-listed Theravance it has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for two different doses of an asthma treatment taken through its Ellipta dry powder inhaler.

The filing of the nNDA is based on data from its clinical development programme for a certain type of long-acting inhaled corticosteroid drug used in the treatment of asthma in sufferers aged 12 and over.

The clinical development programme comprised 48 clinical pharmacology studies in 1,328 subjects and 23 clinical studies in 12,051 patients with asthma.

Shares in GSK had fallen 0.7% to 1,562.50p by 14:10.

NR

Related share prices
GlaxoSmithKline (GSK) share price